

CITATION REPORT

List of articles citing

Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions

DOI: 10.1038/ng.536

Nature Genetics, 2010, 42, 234-9.

Source: <https://exaly.com/paper-pdf/48513765/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
421	TMEM106B is a susceptibility locus for Ftd. 2010 , 6, 184		8
420	[FTLD/ALS as TDP-43 proteinopathies]. 2010 , 50, 1022-4		1
419	Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. 2010 , 9, 978-85		206
418	TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. 2010 , 9, 995-1007		661
417	Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. 2010 , 9, 986-94		171
416	Chromosome 9p21 in amyotrophic lateral sclerosis: the plot thickens. 2010 , 9, 945-7		3
415	Deciphering genetic susceptibility to frontotemporal lobar dementia. <i>Nature Genetics</i> , 2010 , 42, 189-90	36.3	7
414	Open chromatin and diabetes risk. <i>Nature Genetics</i> , 2010 , 42, 190-2	36.3	9
413	The future of genetic research on neurodegeneration. 2010 , 16, 1215-7		17
412	Genetic causes of frontotemporal degeneration. 2010 , 23, 260-8		20
411	Genetics of frontotemporal lobar degeneration. 2010 , 13, S55-62		3
410	Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration?. 2010 , 482, 240-4		8
409	Molecular pathways of frontotemporal lobar degeneration. 2010 , 33, 71-88		34
408	Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. 2011 , 82, 476-86		408
407	Biomarkers in frontotemporal lobar degenerations--progress and challenges. 2011 , 95, 636-48		30
406	On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. 2011 , 95, 649-62		43
405	Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. 2011 , 32, 758.e1-7		28

404	A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. 2011 , 72, 257-68	3018
403	BAG1 is a protective factor for sporadic frontotemporal lobar degeneration but not for Alzheimer's disease. 2011 , 23, 701-7	11
402	The Neuropathology of the Dementing Disorders. 2011 , 235-261	
401	Genetic contributors to frontotemporal lobar degeneration: beyond monogenic disease. 2011 , 11, 988-1001	1
400	Genetic Risk Factors for Dementia. 2011 , 195-234	
399	TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration. 2011 , 278, 3550-68	54
398	Progranulin: a promising therapeutic target for rheumatoid arthritis. 2011 , 585, 3675-80	83
397	The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. 2011 , 332, 478-84	517
396	Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. 2011 , 72, 245-56	3267
395	Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. 2011 , 121, 373-80	82
394	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. 2011 , 122, 673-90	245
393	p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTL and MND/ALS. 2011 , 122, 691-702	369
392	Human genetics as a tool to identify progranulin regulators. 2011 , 45, 532-7	4
391	TMEM106B a novel risk factor for frontotemporal lobar degeneration. 2011 , 45, 516-21	21
390	Progranulin and TDP-43: mechanistic links and future directions. 2011 , 45, 561-73	44
389	Frontotemporal dementia: from Mendelian genetics towards genome wide association studies. 2011 , 45, 500-15	21
388	Alzheimer's genetics in the GWAS era: a continuing story of 'replications and refutations'. 2011 , 11, 246-53	28
387	Alzheimer's disease genetics: current knowledge and future challenges. 2011 , 26, 793-802	69

386	TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. 2011 , 134, 808-15	90
385	ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. 2011 , 183, 1344-53	90
384	Modelling the effects of penetrance and family size on rates of sporadic and familial disease. 2011 , 71, 281-8	74
383	Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. 2011 , 68, 488-97	93
382	Towards unveiling the genetics of neurodegenerative diseases. 2011 , 31, 531-41	52
381	Recent insights into the involvement of progranulin in frontotemporal dementia. 2011 , 9, 632-42	12
380	Genetics of dementia. 2011 , 31, 449-60	37
379	Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. 2011 , 68, 581-6	119
378	An algorithm for genetic testing of frontotemporal lobar degeneration. 2011 , 76, 475-83	57
377	TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. 2011 , 76, 467-74	174
376	Family history of neurodegenerative and vascular diseases in ALS: a population-based study. 2011 , 77, 1363-9	23
375	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. 2012 , 21, 3500-12	174
374	Road to the chromosome 9p-linked ALS/FTD locus. 2012 , 83, 356-7	7
373	Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. 2012 , 21, 1897-906	58
372	Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. 2012 , 135, 709-22	172
371	The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. 2012 , 44, 817-28	141
370	Frontotemporal dementia: implications for understanding Alzheimer disease. 2012 , 2, a006254	101
369	Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. 2012 , 287, 19355-65	91

368	Identification of pharmacological targets in amyotrophic lateral sclerosis through genomic analysis of deregulated genes and pathways. 2012 , 13, 321-33	10
367	TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. 2012 , 32, 11213-27	143
366	TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. 2012 , 79, 717-8	63
365	The genetics and neuropathology of frontotemporal lobar degeneration. 2012 , 124, 353-72	206
364	Frontotemporal lobar degeneration: current knowledge and future challenges. 2012 , 259, 2278-86	31
363	Progranulin axis and recent developments in frontotemporal lobar degeneration. 2012 , 4, 4	14
362	Expanding the genetics of amyotrophic lateral sclerosis and frontotemporal dementia. 2012 , 4, 30	6
361	Next frontiers in the genetic epidemiology of Alzheimer's disease. 2012 , 27, 831-6	3
360	Analysis of optineurin in frontotemporal lobar degeneration. 2012 , 33, 425.e1-2	12
359	Chromosome 9 ALS and FTD locus is probably derived from a single founder. 2012 , 33, 209.e3-8	103
358	Familial Lund frontotemporal dementia caused by C9ORF72 hexanucleotide expansion. 2012 , 33, 1850.e13-6	11
357	The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. 2012 , 135, 723-35	226
356	Investigation of c9orf72 in 4 neurodegenerative disorders. 2012 , 69, 1583-90	83
355	Frontotemporal Lobar Degeneration. 2012 , 724, 114-27	10
354	The genetics and neuropathology of amyotrophic lateral sclerosis. 2012 , 124, 339-52	299
353	Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. 2012 , 26, 841-70	91
352	Genetics of frontotemporal lobar degeneration. 2012 , 3, 52	28
351	Advances in understanding the molecular basis of frontotemporal dementia. 2012 , 8, 423-34	306

350	Losing protein in the brain: the case of progranulin. 2012 , 1476, 172-82	21
349	Genetics of Amyotrophic Lateral Sclerosis. 2012 ,	
348	Alzheimer's disease and the "Valley Of Death": not enough guidance from human brain tissue?. 2013 , 33 Suppl 1, S219-33	18
347	A Major Genetic Factor at Chromosome 9p Implicated in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). 2012 ,	1
346	Genetics of Neurodegenerative Diseases. 2012 , 719-736	0
345	Stratification-score matching improves correction for confounding by population stratification in case-control association studies. 2012 , 36, 195-205	16
344	A quantitative study of the neuropathology of 32 sporadic and familial cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP). 2012 , 38, 25-38	15
343	Progranulin: an emerging target for FTLD therapies. 2012 , 1462, 118-28	33
342	A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. 2012 , 11, 54-65	489
341	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. 2012 , 11, 323-30	830
340	Progranulin: a growth factor, a novel TNFR ligand and a drug target. 2012 , 133, 124-32	80
339	Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. 2012 , 123, 409-17	127
338	Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. 2013 , 1, 36	19
337	Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. 2013 , 79, 416-38	1038
336	Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: a meta-analysis. 2013 , 9, 706-13	29
335	Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. 2013 , 18, 1225-34	251
334	Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. 2013 , 82, 193-229	96
333	Genome-wide association study of Tourette's syndrome. 2013 , 18, 721-8	138

332	Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. 2013 , 1, 68	131
331	Progranulin: at the interface of neurodegenerative and metabolic diseases. 2013 , 24, 597-606	53
330	A pan-European study of the C9orf72 repeat associated with FTLT: geographic prevalence, genomic instability, and intermediate repeats. 2013 , 34, 363-73	208
329	Genetic insights in Alzheimer's disease. 2013 , 12, 92-104	248
328	The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. 2013 , 22, 685-95	116
327	NMNATs, evolutionarily conserved neuronal maintenance factors. 2013 , 36, 632-40	47
326	Mechanisms of granulin deficiency: lessons from cellular and animal models. 2013 , 47, 337-60	49
325	hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. 2013 , 125, 413-23	250
324	Novel progranulin mutations with reduced serum-progranulin levels in frontotemporal lobar degeneration. 2013 , 21, 1260-5	6
323	Current insights into the C9orf72 repeat expansion diseases of the FTLT/ALS spectrum. 2013 , 36, 450-9	129
322	Molecular signature of disease onset in granulin mutation carriers: a gene expression analysis study. 2013 , 34, 1837-45	14
321	The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. 2013 , 21, 102-8	159
320	Batten disease: clinical aspects, molecular mechanisms, translational science, and future directions. 2013 , 28, 1074-100	23
319	The genetics of dementia. 2013 , 33, 417-22	3
318	The FTLT risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. 2014 , 33, 450-67	92
317	TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. 2013 , 126, 781-91	57
316	TMEM106B and frontotemporal lobar degeneration: can over-expression tell us how reductions are beneficial?. 2013 , 126, 696-8	
315	Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. 2013 , 84, 398-401	56

314	Polymorphisms affecting miRNA regulation: a new level of genetic variation affecting disorders and diseases of the human CNS. 2013 , 8, 411-431	3
313	The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. 2013 , 2013, 939786	22
312	Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. 2013 , 5, 6	69
311	Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach. 2013 , 2013, 538765	8
310	Therapeutic and diagnostic challenges for frontotemporal dementia. 2014 , 6, 204	16
309	Association of TMEM106B rs1990622 marker and frontotemporal dementia: evidence for a recessive effect and meta-analysis. 2015 , 43, 325-34	5
308	Wild-type bone marrow transplant partially reverses neuroinflammation in progranulin-deficient mice. 2014 , 94, 1224-36	2
307	TiME for TMEM106B. 2014 , 33, 405-6	1
306	Transmembrane protein 106A is silenced by promoter region hypermethylation and suppresses gastric cancer growth by inducing apoptosis. 2014 , 18, 1655-66	20
305	Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. 2014 , 2, 70	91
304	TMEM106B expression is reduced in Alzheimer's disease brains. 2014 , 6, 17	25
303	Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. 2014 , 8, 75	84
302	TMEM106B and APOE polymorphisms interact to confer risk for late-onset Alzheimer's disease in Han Chinese. 2014 , 121, 283-7	18
301	The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. 2014 , 127, 333-45	124
300	C9ORF72: grabbing a tiger by the tail. 2014 , 127, 311-8	1
299	TMEM106B: a strong FTLN disease modifier. 2014 , 127, 419-22	18
298	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. 2014 , 127, 407-18	97
297	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. 2014 , 127, 397-406	108

296	Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia. 2014 , 127, 377-89	39
295	Dissection of genetic factors associated with amyotrophic lateral sclerosis. 2014 , 262 Pt B, 91-101	116
294	Progranulin in neurodegenerative disease. 2014 , 37, 388-98	119
293	Stuck in traffic: an emerging theme in diseases of the nervous system. 2014 , 37, 66-76	71
292	The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders. 2014 , 28, 30-40	38
291	Progranulin protein levels are differently regulated in plasma and CSF. 2014 , 82, 1871-8	56
290	Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. 2014 , 61, 226-40	71
289	Regulated intramembrane proteolysis of the frontotemporal lobar degeneration risk factor, TMEM106B, by signal peptide peptidase-like 2a (SPPL2a). 2014 , 289, 19670-80	25
288	C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis. 2014 , 76, 120-33	61
287	Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. 2014 , 127, 845-60	135
286	Frontotemporal dementia and its subtypes: a genome-wide association study. 2014 , 13, 686-99	207
285	Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment. 2014 , 9, 117-32	11
284	Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. 2014 , 35, 2658.e1-2658.e5	27
283	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. 2014 , 10, 477-484.e1	118
282	RNA-protein interactions in unstable microsatellite diseases. 2014 , 1584, 3-14	43
281	Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. 2014 , 35, 1473-82	38
280	TMEM106B influences volume of left-sided temporal lobe and interhemispheric structures in the general population. 2014 , 76, 503-8	14
279	C9orf72; abnormal RNA expression is the key. 2014 , 262 Pt B, 102-10	13

278 Genetica delle demenze degenerative. **2015**, 15, 1-9

277	Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. 2015 , 130, 511-23	58
276	Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. 2015 , 41, 858-81	130
275	The role of RNA metabolism in neurological diseases. 2015 , 18, 5-14	9
274	TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III. 2015 , 8, 85	18
273	The genetic basis of amyotrophic lateral sclerosis: recent breakthroughs. 2015 , 327	10
272	Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. 2015 , 7, 171	75
271	Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology. 2015 , 74, 75-84	36
270	Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. 2015 , 35, 354-89	211
269	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. 2015 , 130, 877-89	176
268	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. 2015 , 129, 469-91	165
267	Genetics and underlying pathology of dementia. 2015 , 25, 113-24	22
266	Frontotemporal dementia: a bridge between dementia and neuromuscular disease. 2015 , 1338, 71-93	86
265	A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy. 2015 , 72, 414-22	33
264	The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis. 2015 , 12, 326-39	39
263	The TMEM106B locus and TDP-43 pathology in older persons without FTLD. 2015 , 84, 927-34	55
262	A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. 2015 , 36, 2904.e13-26	34
261	Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. 2015 , 11, 1277-85	59

260 Movement Disorder Genetics. **2015,**

259 FTD and ALS--translating mouse studies into clinical trials. **2015, 11, 360-6** 55

258 The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. **2015, 11, 1407-1416** 126

257 Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). **2015, 31, 263-73** 88

256 Genetics of Frontotemporal Dementia. **2015, 75-105**

255 Update on Hippocampal Sclerosis. **2015, 15, 67** 20

254 Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. **2015, 85, 2116-25** 119

253 Epidemiology and molecular mechanism of frontotemporal lobar degeneration/amyotrophic lateral sclerosis with repeat expansion mutation in C9orf72. **2015, 29, 85-94** 14

252 Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. **2015, 30, 805-12** 29

251 Heterogeneity of Parkinsonism in Familial Frontotemporal Dementia: Insights from Genetic Clues on the Pathogenesis. **2016, 6,**

250 . **2016,** 6

249 Geneticsof frontotemporal dementia and related disorders. 185-196

248 Frontotemporal Lobar Degeneration and MicroRNAs. **2016, 8, 17** 16

247 A Novel Splice-Acceptor Site Mutation in GRN (c.709-2 A>T) Causes Frontotemporal Dementia Spectrum in a Large Family from Southern Italy. **2016, 53, 475-85** 9

246 Neuropathology offrontotemporal dementia and related disorders. 165-184 1

245 Paving the road for the study of epigenetics in neurodegenerative diseases. **2016, 132, 483-5** 5

244 ALS: A bucket of genes, environment, metabolism and unknown ingredients. **2016, 142, 104-129** 124

243 "New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). **2016, 75, 482-98** 97

242	Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes. 2016 , 25, 2681-2697	38
241	Intramembrane proteolysis within lysosomes. 2016 , 32, 51-64	12
240	Impaired protein degradation in FTL and related disorders. 2016 , 32, 122-139	47
239	Frontotemporal dementia. 2016 , 49-63	2
238	The Lysosomal Trafficking Transmembrane Protein 106B Is Linked to Cell Death. 2016 , 291, 21448-21460	8
237	Genetics of FTL: overview and what else we can expect from genetic studies. 2016 , 138 Suppl 1, 32-53	89
236	C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling. 2016 , 27, 3040-3051	114
235	What we know about TMEM106B in neurodegeneration. 2016 , 132, 639-651	59
234	Progranulin Controls Sepsis via C/EBP β -Regulated Il10 Transcription and Ubiquitin Ligase/Proteasome-Mediated Protein Degradation. 2016 , 197, 3393-3405	17
233	Catastrophic cliffs: a partial suggestion for selective vulnerability in neurodegenerative diseases. 2016 , 44, 659-61	8
232	Molecular Pathways Leading to the Clinical Phenomenology of Frontotemporal Dementia. 2016 , 533-546	1
231	Decoding ALS: from genes to mechanism. 2016 , 539, 197-206	1040
230	The Lysosome in Aging-Related Neurodegenerative Diseases. 2016 , 137-179	2
229	Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. 2016 , 2, 86-94	46
228	Frontotemporal dementia: insights into the biological underpinnings of disease through gene co-expression network analysis. 2016 , 11, 21	30
227	Genome-wide estimate of the heritability of Multiple System Atrophy. 2016 , 22, 35-41	32
226	A novel Alzheimer disease locus located near the gene encoding tau protein. 2016 , 21, 108-17	175
225	Adult neurogenesis and neurodegenerative diseases: A systems biology perspective. 2017 , 174, 93-112	95

224	Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. 2017 , 27, 723-736	76
223	HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort. 2017 , 373, 124-128	10
222	Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. 2017 , 53, 193.e17-193.e25	15
221	Weighted Protein Interaction Network Analysis of Frontotemporal Dementia. 2017 , 16, 999-1013	28
220	Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research?. 2017 , 105, 283-299	121
219	C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease. 2017 , 18, 267-276	36
218	Screening with an NMNAT2-MSD platform identifies small molecules that modulate NMNAT2 levels in cortical neurons. 2017 , 7, 43846	22
217	Frontotemporal dementia. 2017 , 199-249	1
216	Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy. 2017 , 377, 65-71	5
215	The TMEM106B risk allele is associated with lower cortical volumes in a clinically diagnosed frontotemporal dementia cohort. 2017 , 88, 997-998	5
214	Latest emerging functions of SPP/SPPL intramembrane proteases. 2017 , 96, 372-382	25
213	Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia. 2017 , 140, 1437-1446	38
212	Differential Aging Analysis in Human Cerebral Cortex Identifies Variants in TMEM106B and GRN that Regulate Aging Phenotypes. 2017 , 4, 404-415.e5	65
211	Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. 2017 , 32, 246-255	34
210	[Pathomechanisms and clinical aspects of frontotemporal lobar degeneration]. 2017 , 88, 163-172	2
209	A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression. 2017 , 101, 643-663	46
208	Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. 2017 , 26, 4861-4872	61
207	Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. 2017 , 140, 3081-3104	77

206	Modifiers of GRN-Associated Frontotemporal Lobar Degeneration. 2017 , 23, 962-979	17
205	Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice. 2017 , 95, 281-296.e6	92
204	TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3). 2017 , 59, 221.e1-221.e7	3
203	Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency. 2017 , 5, 9	31
202	Dominant LGMD2A: alternative diagnosis or hidden digenism?. 2017 , 140, e7	5
201	Factors influencing the age at onset in familial frontotemporal lobar dementia: Important weight of genetics. 2017 , 3, e203	8
200	Autophagy-Lysosome Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration. 2017 ,	1
199	Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data. 2017 , 14, e1002287	56
198	Recent advances in the molecular genetics of frontotemporal lobar degeneration. 2017 , 32, 7-16	26
197	Intracellular Proteolysis of Progranulin Generates Stable, Lysosomal Granulins that Are Haploinsufficient in Patients with Frontotemporal Dementia Caused by Mutations. 2017 , 4,	67
196	Frontotemporal dementia. 2018 , 148, 409-430	33
195	TDP-43 pathology in multiple system atrophy: colocalization of TDP-43 and β -synuclein in glial cytoplasmic inclusions. 2018 , 44, 707-721	19
194	Molecular regulations and therapeutic targets of Gaucher disease. 2018 , 41, 65-74	8
193	Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. 2018 , 75, 860-875	56
192	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. 2018 , 67, 84-94	13
191	Genetic Modifiers in Neurodegeneration. 2018 , 6, 11-19	8
190	Progranulin: Functions and neurologic correlations. 2018 , 90, 118-125	7
189	The Post-GWAS Era: From Association to Function. 2018 , 102, 717-730	294

188	Genetics and Epigenetics in the Neurodegenerative Disorders of the Central Nervous System. 2018 , 1-20	1
187	GFRA2 in GRN-related frontotemporal lobar degeneration. 2018 , 17, 488-489	
186	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. 2018 , 17, 548-558	60
185	Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer's Disease and Frontotemporal Dementia. 2018 , 62, 913-932	31
184	The Genetics of Expansions. 2018 , 8,	13
183	Atypical parkinsonian syndromes: a general neurologist's perspective. 2018 , 25, 41-58	27
182	In search of lost trafficking. 2018 , 141, 3282-3285	
181	Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic-rescue by TMEM106B knockdown. 2018 , 141, 3428-3442	22
180	Variation in TMEM106B in chronic traumatic encephalopathy. 2018 , 6, 115	21
179	TMEM106B, a risk factor for FTLD and aging, has an intrinsically disordered cytoplasmic domain. 2018 , 13, e0205856	2
178	Monogenic inheritance in early-onset dementia: illustration in Alzheimer's disease and frontotemporal lobar dementia. 2018 , 16, 289-297	4
177	Alzheimer's Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing. 2018 , 22, 505-513	24
176	Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity. 2018 , 6, 42	14
175	Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ϵ haplotype status: a community-based cohort study. 2018 , 17, 773-781	64
174	Fitting TDP-43 into the APOE ϵ and neurodegeneration story. 2018 , 17, 735-737	2
173	Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency. 2018 , 13, 32	17
172	TMEM106B haplotypes have distinct gene expression patterns in aged brain. 2018 , 13, 35	15
171	The lysosomal function of progranulin, β guardian against neurodegeneration. 2018 , 136, 1-17	87

170	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. 2018 , 136, 389-404	27
169	The role of lysosomes and autophagosomes in frontotemporal lobar degeneration. 2019 , 45, 244-261	12
168	Lysosome trafficking and signaling in health and neurodegenerative diseases. 2019 , 122, 94-105	130
167	LATE to the PART-y. 2019 , 142, e47	25
166	Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD. 2019 , 13, 548	25
165	Genome Wide Association Study and Next Generation Sequencing: A Glimmer of Light Toward New Possible Horizons in Frontotemporal Dementia Research. 2019 , 13, 506	15
164	Education modulates brain maintenance in presymptomatic frontotemporal dementia. 2019 , 90, 1124-1130	10
163	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. 2019 , 142, 1503-1527	454
162	Immune Signaling in Neurodegeneration. 2019 , 50, 955-974	105
161	Progranulin and Central Nervous System Disorders. 2019 ,	
160	Divergent patterns of TDP-43 and tau pathologies in primary progressive aphasia. 2019 , 85, 630-643	23
159	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. 2019 , 85, 801-811	23
158	Genome-wide analyses as part of the international FTLT-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLT. 2019 , 137, 879-899	50
157	Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. 2019 , 99, 993-1007	29
156	Recent advances in the genetics of frontotemporal dementia. 2019 , 7, 41-52	22
155	Genetics and molecular mechanisms of frontotemporal lobar degeneration: an update and future avenues. 2019 , 78, 98-110	31
154	Review: Clinical, genetic and neuroimaging features of frontotemporal dementia. 2019 , 45, 6-18	18
153	Review: Modelling the pathology and behaviour of frontotemporal dementia. 2019 , 45, 58-80	9

152	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. 2019 , 137, 227-238	32
151	Therapeutic trial design for frontotemporal dementia and related disorders. 2019 , 90, 412-423	16
150	C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. 2019 , 137, 1-26	37
149	Review: Neuropathology of non-tau frontotemporal lobar degeneration. 2019 , 45, 19-40	57
148	UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. 2019 , 73, 190-199	19
147	The TMEM106B FTLN-protective variant, rs1990621, is also associated with increased neuronal proportion. 2020 , 139, 45-61	21
146	Omics in Neurodegenerative Disease: Hope or Hype?. 2020 , 36, 152-159	20
145	Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms. 2020 , 143, 303-319	26
144	The complex relationship between genotype, pathology and phenotype in familial dementia. 2020 , 145, 105082	1
143	Genetics of Chronic Traumatic Encephalopathy. 2020 , 40, 420-429	2
142	ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. 2020 , 140, 449-461	3
141	A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination. 2020 , 143, 2255-2271	10
140	Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. 2020 , 143, 1905-1919	14
139	TMEM106B, an unexpected point of contact between FTD, ageing and a hypomyelination disorder. 2020 , 143, 1628-1631	
138	Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology. 2020 , 107, 496-508.e6	12
137	The FTLN Risk Factor TMEM106B Regulates the Transport of Lysosomes at the Axon Initial Segment of Motoneurons. 2020 , 30, 3506-3519.e6	19
136	Impairment of Lysosome Function and Autophagy in Rare Neurodegenerative Diseases. 2020 , 432, 2714-2734	23
135	Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. 2020 , 91, 167.e1-167.e9	10

134	Functional genomics links genetic origins to pathophysiology in neurodegenerative and neuropsychiatric disease. 2020 , 65, 117-125	2
133	Genetic architecture of neurodegenerative dementias. 2020 , 168, 108014	3
132	Genetic Diversity in Frontotemporal Dementia. 2020 , 54, 13-23	5
131	TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy. 2019 , 11, 376	9
130	Screening of dementia genes by whole-exome sequencing in Spanish patients with early-onset dementia: likely pathogenic, uncertain significance and risk variants. 2020 , 93, e1-e9	4
129	Aged Tmem106b knockout mice display gait deficits in coincidence with Purkinje cell loss and only limited signs of non-motor dysfunction. 2021 , 31, 223-238	5
128	Cellular and physiological functions of C9ORF72 and implications for ALS/FTD. 2021 , 157, 334-350	16
127	Fronto-temporal dementia risk gene has opposing effects in different lysosomal storage disorders. 2021 , 3, fcaa200	1
126	Whole-exome sequencing of Finnish patients with vascular cognitive impairment. 2021 , 29, 663-671	0
125	A novel temporal-predominant neuro-astroglial tauopathy associated with TMEM106B gene polymorphism in FTL/ALS-TDP. 2021 , 31, 267-282	1
124	Delineating the Genetic Component of Gene Expression in Major Depression. 2021 , 89, 627-636	16
123	Lysosomal Dysfunction and Other Pathomechanisms in FTL/ALS-TDP: Evidence from Progranulin Genetics and Biology. 2021 , 1281, 219-242	4
122	Genetic overlap between Alzheimer's disease and depression mapped onto the brain.	
121	Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders. 2021 , 141, 327-339	13
120	Mendelian and Sporadic FTD: Disease Risk and Avenues from Genetics to Disease Pathways Through In Silico Modelling. 2021 , 1281, 283-296	1
119	rs1990622 variant associates with Alzheimer's disease and regulates TMEM106B expression in human brain tissues. 2021 , 19, 11	27
118	7p21.3 Together With a 12p13.32 Deletion in a Patient With Microcephaly-Does 12p13.32 Locus Possibly Comprises a Candidate Gene Region for Microcephaly?. 2021 , 14, 613091	0
117	TMEM106B in humans and Vac7 and Tag1 in yeast are predicted to be lipid transfer proteins.	

116	The Role of White Matter Dysfunction and Leukoencephalopathy/Leukodystrophy Genes in the Aetiology of Frontotemporal Dementias: Implications for Novel Approaches to Therapeutics. 2021 , 22,	2
115	Loss of Tmem106b leads to cerebellum Purkinje cell death and motor deficits. 2021 , 31, e12945	2
114	Emerging genetic complexity and rare genetic variants in neurodegenerative brain diseases. 2021 , 13, 59	4
113	A Mendelian Randomization Study of Plasma Homocysteine Levels and Cerebrovascular and Neurodegenerative Diseases. 2021 , 12, 653032	2
112	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. 2021 , 89, 825-835	3
111	TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy.	
110	Genome-wide analyses of smoking behaviors in schizophrenia: Findings from the Psychiatric Genomics Consortium. 2021 , 137, 215-224	3
109	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. 2021 , 17, 1628-1640	4
108	Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. 2021 , 12, 679927	1
107	TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. 2021 , 142, 629-642	3
106	Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. 2021 , 154, 105360	27
105	Genetic Overlap Between Alzheimer's Disease and Depression Mapped Onto the Brain. 2021 , 15, 653130	2
104	Tweaking Progranulin Expression: Therapeutic Avenues and Opportunities. 2021 , 14, 713031	3
103	TMEM106B in humans and Vac7 and Tag1 in yeast are predicted to be lipid transfer proteins. 2021 ,	1
102	Molecular Pathways Involved in Frontotemporal Lobar Degeneration with TDP-43 Proteinopathy: What Can We Learn from Proteomics?. 2021 , 22,	1
101	Delivering progranulin to neuronal lysosomes protects against excitotoxicity. 2021 , 297, 100993	5
100	Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes. 2022 , 70, 239-255	1
99	Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology.	

98	Uncovering the impact of noncoding variants in neurodegenerative brain diseases. 2021 ,	1
97	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. 2021 , 11, 451	0
96	Common genetic variation is associated with longitudinal decline and network features in behavioral variant frontotemporal degeneration. 2021 , 108, 16-23	0
95	Disease-related cortical thinning in presymptomatic granulin mutation carriers. 2021 , 29, 102540	2
94	A growth-factor-activated lysosomal K channel regulates Parkinson's pathology. 2021 , 591, 431-437	15
93	Single-cell deconvolution of 3,000 post-mortem brain samples for eQTL and GWAS dissection in mental disorders.	4
92	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. 2021 , 144, 2798-2811	2
91	Molecular Genetics of Frontotemporal Dementia.	2
90	Frontotemporal Lobar Degeneration with TDP-43 Pathology. 393-403	1
89	Genetic Risk Factors for Sporadic Frontotemporal Dementia. 2018 , 147-186	1
88	Clinical Neurogenetics. 2012 , 704-734	3
87	Genetic architecture of common non-Alzheimer's disease dementias. 2020 , 142, 104946	16
86	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels.	0
85	Gene expression imputation provides insight into the genetic architecture of frontotemporal dementia.	0
84	Recent advances in understanding frontotemporal degeneration. 2019 , 8,	8
83	NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies. 2016 , 14, e1002472	74
82	Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case-control study. 2017 , 14, e1002272	39
81	Evidence of the innate antiviral and neuroprotective properties of progranulin. 2014 , 9, e98184	13

80	A novel network analysis approach reveals DNA damage, oxidative stress and calcium/cAMP homeostasis-associated biomarkers in frontotemporal dementia. 2017 , 12, e0185797	14
79	Loss of Tmem106b exacerbates FTLD pathologies and causes motor deficits in progranulin-deficient mice. 2020 , 21, e50197	18
78	Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice. 2020 , 21, e50219	22
77	Loss of TMEM106B potentiates lysosomal and FTLD-like pathology in progranulin-deficient mice. 2020 , 21, e50241	17
76	Neuronal Development-Related miRNAs as Biomarkers for Alzheimer's Disease, Depression, Schizophrenia and Ionizing Radiation Exposure. 2021 , 28, 19-52	16
75	Identification of misdiagnosed fronto-temporal dementia using APOE genotype and phenotype-genotype correlation analyses. 2014 , 11, 182-91	7
74	Genome-wide association studies in neurology. 2014 , 2, 124	18
73	Genetics of Neurodegeneration. 22-25	
72	The Penn ADCC: Integrating Neurodegenerative Disease Research Across Disciplines, Conditions, and Population Groups. 2015 , 3-12	
71	A dementia-associated risk variant near TMEM106B alters chromatin architecture and gene expression.	
70	Autosomal Dominant Frontotemporal Lobar Degeneration: From Genotype to Phenotype. 2018 , 123-145	
69	TMEM106B, a risk factor for FTLD and aging, has an intrinsically disordered cytoplasmic domain.	
68	Progranulin Regulations of Lysosomal Homeostasis and Its Involvement in Neurodegenerative Diseases. 2019 , 85-103	
67	The TMEM106B rs1990621 protective variant is also associated with increased neuronal proportion.	1
66	Genetic contributions to sporadic frontotemporal dementia. 2020 , 71-88	
65	Delineating the Genetic Component of Gene Expression in Major Depression.	0
64	ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's Disease and Dementia with Lewy Bodies.	
63	Molecular Network Analysis of Target RNAs and Interacting Proteins of TDP-43, a Causative Gene for the Neurodegenerative Diseases ALS/FTLD. 314-335	

62	Molecular Network Analysis of Target RNAs and Interacting Proteins of TDP-43, a Causative Gene for the Neurodegenerative Diseases ALS/FTLD. 964-985	
61	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 209-248	2
60	TDP-43 in aging and Alzheimer's disease - a review. 2011 , 4, 147-55	112
59	Circulating progranulin as a biomarker for neurodegenerative diseases. 2012 , 1, 180-90	19
58	C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity. 2014 , 3, 1-18	20
57	New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia. 2021 , 72, 131-139	1
56	Age-Dependent Formation of TMEM106B Amyloid Filaments in Human Brain.	0
55	Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases. 2021 , 8, 735136	3
54	TDP-43 pathology: from noxious assembly to therapeutic removal.. 2022 , 102229	0
53	Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.. 2022 ,	2
52	Amyloid fibrils in frontotemporal lobar degeneration with TDP-43 inclusions are composed of TMEM106B, rather than TDP-43.	
51	Genetics of cognitive dysfunction in Parkinson's disease.. 2022 , 269, 195-226	0
50	Neuronal endolysosomal transport and lysosomal functionality in maintaining axonostasis.. 2022 , 221,	3
49	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. 2021 ,	2
48	Mobile elements in human population-specific genome and phenotype divergence.	1
47	Body Complexion and Circulating Lipids in the Risk of TDP-43 Related Disorders.. 2022 , 14, 838141	1
46	Age-dependent formation of TMEM106B amyloid filaments in human brains.. 2022 ,	6
45	Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases.. 2022 ,	5

44	Amyloid fibrils in disease FTLD-TDP are composed of TMEM106B not TDP-43.. 2022,	5
43	Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.. 2022,	0
42	TMEM106B deficiency impairs cerebellar myelination and synaptic integrity with Purkinje cell loss.. 2022, 10, 33	1
41	Dissecting the clinical heterogeneity of early-onset Alzheimer's disease.. 2022,	3
40	An unexpected protein aggregate in diseased and ageing brains.. 2022,	
39	Protein interaction network analysis reveals genetic enrichment of immune system genes in frontotemporal dementia.. 2022, 116, 67-79	0
38	TDP-43 Pathology in Alzheimer's Disease.. 2021, 16, 84	8
37	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations.. 2021,	0
36	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. 2021, 143, 15	2
35	Flying under the radar: TMEM106B(120-254) fibrils break out in diverse neurodegenerative disorders.. 2022, 185, 1290-1292	
34	Generic amyloid fibrillation of TMEM106B in patient with Parkinson's disease dementia and normal elders.. 2022,	0
33	TMEM106B is increased in Multiple Sclerosis plaques, and deletion causes accumulation of lipid after demyelination.	0
32	Genome wide association studies for Alzheimer's disease: bigger is not always better.	1
31	How network-based approaches can complement gene identification studies in frontotemporal dementia. 2022,	
30	Inflammation and neuronal gene expression changes differ in early vs late chronic traumatic encephalopathy brain.	
29	Synaptic proteomics reveal distinct molecular signatures of cognitive change and C9ORF72 repeat expansion in the human ALS cortex.	
28	Neuroimmune dysfunction in frontotemporal dementia: Insights from progranulin and C9orf72 deficiency. 2022, 76, 102599	
27	Frontotemporal lobar degeneration. 2023, 337-360	

26	Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer and coronary disease pathways.	0
25	Cell-type-specific cis-eQTLs in eight human brain cell types identify novel risk genes for psychiatric and neurological disorders. 2022 , 25, 1104-1112	1
24	Association between risk polymorphisms for neurodegenerative diseases and cognition in colombian patients with frontotemporal dementia. 13,	
23	TMEM106B Acts as a Modifier of Cognitive and Motor Functions in Amyotrophic Lateral Sclerosis. 2022 , 23, 9276	1
22	Emerging cellular themes in leukodystrophies. 10,	0
21	Identification of TMEM106B amyloid fibrils provides an updated view of TMEM106B biology in health and disease.	0
20	Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers.	0
19	Two FTD-ALS genes converge on the endosomal pathway to induce TDP-43 pathology and degeneration. 2022 , 378, 94-99	1
18	Frontotemporal degeneration genetic risk loci and transcription regulation as a possible mechanistic link to disease risk. 2022 , 101, e31078	0
17	Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia. 2022 ,	0
16	Synaptic proteomics reveal distinct molecular signatures of cognitive change and C9ORF72 repeat expansion in the human ALS cortex. 2022 , 10,	2
15	Cell-subtype specific effects of genetic variation in the aging and Alzheimer cortex.	0
14	Accumulation of TMEM106B C-terminal fragments in neurodegenerative disease and aging.	0
13	Loss of TMEM106B exacerbates C9ALS/FTD DPR pathology by disrupting autophagosome maturation. 16,	0
12	Causal association between systemic lupus erythematosus and the risk of dementia: A Mendelian randomization study. 13,	0
11	Cross-helical filaments of Tau and TMEM106B in Gray and White Matter of Multiple System Tauopathy with presenile Dementia.	0
10	Advances in sequencing technologies for amyotrophic lateral sclerosis research. 2023 , 18,	0
9	The major TMEM106B dementia risk allele affects TMEM106B protein levels and myelin lipid homeostasis in the ageing human hippocampus.	0

- 8 Lack of a protective effect of the Tmem106b protective SNP in the Grn knockout mouse model for frontotemporal lobar degeneration. **2023**, 11,
- 7 Inflammation and neuronal gene expression changes differ in early versus late chronic traumatic encephalopathy brain. **2023**, 16,
- 6 Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer's and coronary disease pathways. **2023**, 26, 106408
- 5 The role of plasma cortisol in dementia, epilepsy, and multiple sclerosis: A Mendelian randomization study. 14,
- 4 Identification of a de novo Mutation in TMEM106B in a Saudi Child Causes Hypomyelination Leukodystrophy. **2023**, 10, 038-041
- 3 TMEM106B coding variant is protective and deletion detrimental in a mouse model of tauopathy.
- 2 Case report: TMEM106B haplotype alters penetrance of GRN mutation in frontotemporal dementia family. 14,
- 1 Progranulin deficiency results in sex-dependent alterations in microglia in response to demyelination.